Fellowship · Los Angeles, CA
Sponsored by University of Southern California/Los Angeles General Medical Center (USC/LA General)
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1.
Autophagy · 2021 · 2,291 citations · Heinz-Josef Lenz
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
The New England journal of medicine · 2022 · 1,350 citations · Christina To
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
Lancet (London, England) · 2025 · 275 citations · Anthony El-Khoueiry
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
The Lancet. Oncology · 2022 · 997 citations · Anthony El-Khoueiry
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
The New England journal of medicine · 2023 · 739 citations · Gino In
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 555 citations · Tanya Dorff
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
Lancet (London, England) · 2025 · 190 citations · Heinz-Josef Lenz
Ponsegromab for the Treatment of Cancer Cachexia.
The New England journal of medicine · 2024 · 260 citations · Andrew Hendifar